Opendata, web and dolomites

TheraPD TERMINATED

TheraPD: Smart and safer automated peritoneal dialysis by means of sterile connectivity, bio-sensors control systems and more biocompatible solutions for preventing rapid degradation of peritoneal mem

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TheraPD project word cloud

Explore the words cloud of the TheraPD project. It provides you a very rough idea of what is the project "TheraPD" about.

monitor    either    cavity    least    solution    pd    demonstrated    equipped    capacity    esrd    doubled    rapid    biosensors    significantly    europeans    renal    hospital    world    therapy       generating    prevents    dialysis    automated    poorly    dropout    haemodialysis    patients    risk    peritonitis    penetrating    cycler    drawbacks    expanding    transplants    therapd    million    35    healthcare    frequency    roi    kidney    solving    individual    spending    zero    stage    3h    budgets    consist    previously    launch    glucose    sterile    worldwide    comfort    250    ec    ph    profit    benefits    peritoneal    machine    outcome    reduce    times    body    innovation    causing    eligible    people    safety    65    efficient    biosensing    15    cells    mesothelium    connected    solutions    almost    societal    week    undergo    degradation    treatment    7m    transplant    clinical    avoids    entails    market    irreversible    safe    connector    disease    home       innovative    nhs    overfilling    biocompatible    concentration    earning    ultrafiltration    11    patient    special    date    renders    unmet    membrane    dialysate    solid    customize    prescription   

Project "TheraPD" data sheet

The following table provides information about the project.

Coordinator
GLOMERIA THERAPEUTICS SOCIETA' A RESPONSABILITA' LIMITATA 

Organization address
address: VIA PADRE UGOLINO FRASCA, SNC
city: CHIETI
postcode: 66100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://youtu.be/YGVClIl33qs
 Total cost 2˙838˙126 €
 EC max contribution 2˙838˙126 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLOMERIA THERAPEUTICS SOCIETA' A RESPONSABILITA' LIMITATA IT (CHIETI) coordinator 2˙838˙126.00

Map

 Project objective

2.7 million People worldwide (250,000 Europeans) have kidney transplants or undergo a dialysis treatment because of irreversible end-stage renal disease (ESRD). This number has more than doubled over the past 15 years and involves 3-5% of NHS budgets. Current therapy consist in either a kidney transplant, haemodialysis connected to a machine at the hospital for at least 3h, 3 times a week, or the better-outcome cost-effective home-based peritoneal dialysis (PD). Although widely demonstrated to have greater results and to be cost-effective, PD is only used in 11% of the cases because of its drawbacks: peritonitis (35% dropout), poorly biocompatible solutions available, and overfilling of the peritoneal cavity causing rapid degradation on the mesothelium membrane. Our innovative TheraPD solution provide the most safe and efficient automated peritoneal dialysis therapy to date. It entails a comprehensive system composed by a sterile connector (renders peritonitis risk almost zero), a biosensing control system (avoids overfilling), and a new biocompatible dialysate which prevents degradation of peritoneal membrane cells. Another innovation is that our cycler will be equipped with special biosensors to measure the concentration of glucose and pH, this allows to customize the dialysis prescription according to the ultrafiltration capacity of the patient, increases safety level of the treatment and it allows to monitor the uptake of glucose by the patient. By solving these unmet clinical needs, we will increase PD usage by expanding it to people who were not previously eligible, reduce treatment frequency or duration, customize the dialysis treatment according to the response of the patient’s body, increase patients’ comfort and significantly reduce healthcare spending. With EC’s support we will achieve all these societal and individual benefits while earning €4.7M profit, penetrating 1.15% of the world market, and generating a solid ROI of 1.65 after 5 years from launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More